1
|
Kumar PS, Wiczer T, Rosen L, Pollauf AJ, Zheng A, Palettas M, Azali L, Bhat SA, Byrd JC, Grever MR, Rogers KA, Woyach JA, Kittai AS. Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy. Leukemia 2023:10.1038/s41375-023-01927-8. [PMID: 37231141 DOI: 10.1038/s41375-023-01927-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
|
2
|
Bhat SA, Gambril J, Azali L, Chen ST, Rosen L, Palettas M, Wiczer TE, Kalathoor S, Zhao Q, Rogers KA, Kittai A, Grever M, Awan F, Ruz P, Byrd JC, Woyach J, Addison D. Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood 2022; 140:2142-2145. [PMID: 35917449 PMCID: PMC10405526 DOI: 10.1182/blood.2022016953] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Accepted: 07/09/2022] [Indexed: 11/20/2022] Open
Abstract
Acalabrutinib, a next-generation Bruton's tyrosine kinase inhibitor (BTKi), associates with dramatic efficacy against B-cell malignancies. Recently, unexplained ventricular arrhythmias (VAs) with next-generation BTKi-therapy have been reported. Yet, whether acalabrutinib associates with VAs in long-term follow-up is unknown. Leveraging a large-cohort of 290 consecutive B-cell malignancy patients treated with acalabrutinib from 2014 to 2020, we assessed the incidence of VAs. The primary-endpoint was incident VA development (ventricular fibrillation, ventricular tachycardia, and symptomatic premature ventricular contractions). Probability-scores were assessed to determine likelihood of acalabrutinib-association. Incident rates as function of time-on-therapy were calculated. Weighted average observed incidence rates were compared with expected population rates using relative-risks. Absolute excess risk (AER) for acalabrutinib-associated VAs was estimated. Over 1063 person-years of follow-up, there were 8 cases of incident-VAs, including 6 in those without coronary disease (CAD) or heart failure (HF) and 1 sudden-death; median time-to-event 14.9 months. Among those without prior ibrutinib-use, CAD, or HF, the weighted average incidence was 394 per 100 000 person years compared with a reported incidence of 48.1 among similar-aged non-BTKi-treated subjects (relative risk, 8.2; P < .001; AER, 346). Outside of age, no cardiac or electrocardiographic variables associated with VA development. Collectively, these data suggest VAs may be a class-effect of BTKi therapies.
Collapse
|
3
|
Chen ST, Azali L, Rosen L, Zhao Q, Wiczer T, Palettas M, Gambril J, Kola-Kehinde O, Ruz P, Kalathoor S, Rogers K, Kittai A, Grever M, Awan F, Byrd JC, Woyach J, Bhat SA, Addison D. Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. J Hematol Oncol 2022; 15:92. [PMID: 35836241 PMCID: PMC9281099 DOI: 10.1186/s13045-022-01302-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Accepted: 04/22/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Post-market analyses revealed unanticipated links between first-generation Bruton's tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel selective second (next)-generation BTKi therapy, acalabrutinib, is unknown. METHODS Leveraging a large cohort of consecutive B cell cancer patients treated with acalabrutinib from 2014 to 2020, we assessed the incidence and ramifications of new or worsened hypertension [systolic blood pressure (SBP) ≥ 130 mmHg] after acalabrutinib initiation. Secondary endpoints were major cardiovascular events (MACE: arrhythmias, myocardial infarction, stroke, heart failure, cardiac death) and disease progression. Observed incident hypertension rates were compared to Framingham heart-predicted and ibrutinib-related rates. Multivariable regression and survival analysis were used to define factors associated with new/worsened hypertension and MACE, and the relationship between early SBP increase and MACE risk. Further, the effect of standard antihypertensive classes on the prevention of acalabrutinib-related hypertension was assessed. RESULTS Overall, from 280 acalabrutinib-treated patients, 48.9% developed new/worsened hypertension over a median of 41 months. The cumulative incidence of new hypertension by 1 year was 53.9%, including 1.7% with high-grade (≥ 3) hypertension. Applying the JNC 8 cutoff BP of ≥ 140/90 mmHg, the observed new hypertension rate was 20.5% at 1 year, > eightfold higher than the Framingham-predicted rate of 2.4% (RR 8.5, P < 0.001), yet 34.1% lower than ibrutinib (12.9 observed-to-expected ratio, P < 0.001). In multivariable regression, prior arrhythmias and Black ancestry were associated with new hypertension (HR 1.63, HR 4.35, P < 0.05). The degree of SBP rise within 1 year of treatment initiation predicted MACE risk (42% HR increase for each + 5 mmHg SBP rise, P < 0.001). No single antihypertensive class prevented worsened acalabrutinib-related hypertension. CONCLUSIONS Collectively, these data suggest that hypertension may be a class effect of BTKi therapies and precedes major cardiotoxic events.
Collapse
|
4
|
Kleinplatz PJ, Charest M, Paradis N, Rosen L, Ramsay TO. The effectiveness of in-person versus remote group couples therapy for the treatment of low sexual desire or frequency. J Sex Med 2022. [DOI: 10.1016/j.jsxm.2022.03.359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
5
|
Moreno V, Lin J, Tan D, Lassen U, Leyvraz S, Liu Y, Patel J, Rosen L, Solomon B, Rudolph M, Norenberg R, Schulz A, Fellous M, Brega N, Shen L, Kummar S, Drilon A. 61P Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
6
|
Chen ST, Azali L, Rosen L, Zhao Q, Wiczer T, Palettas M, Gambril J, Kola-Kehinde O, Ruz P, Rogers K, Kittai A, Grever M, Awan F, Byrd JC, Bhat SA, Addison D. INCIDENT HYPERTENSION AND CLINICAL OUTCOMES AFTER ACALABRUTINIB INITIATION FOR B-CELL MALIGNANCIES. J Am Coll Cardiol 2022. [DOI: 10.1016/s0735-1097(22)02821-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Drilon A, Lin J, Lassen U, Leyvraz S, Liu Y, Patel J, Rosen L, Solomon B, Norenberg R, Dima L, Brega N, Shen L, Moreno V, Kummar S, Tan D. P53.02 Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Naing A, Rosen L, Camidge R, Khalil D, Davies J, Miles D, Patel M, Cockle P, Champion B, Krige D, Lillie T. 1011P FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
9
|
Garcia VM, Lin J, Patel J, Lassen U, Solomon B, Rosen L, Leyvraz S, Tan D, Reeves J, Beckmann G, Rudolph M, Wierzbinska J, Dima L, Brega N, Kummar S, Drilon A. 162P Long-term efficacy and genomic characteristics of patients with TRK fusion lung cancer treated with larotrectinib. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)02004-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Tan D, Farago A, Kummar S, Moreno V, Patel J, Lassen U, Solomon B, Rosen L, Leyvraz S, Reeves J, Brega N, Dima L, Childs B, Drilon A. MA11.09 Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.253] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Drilon A, Moreno V, Patel J, Lassen U, Solomon B, Rosen L, Leyvraz S, Tan D, Reeves J, Dima L, Brega N, Kummar S, Farago A. MO01.35 Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
12
|
Rosen L. Online Resources in Blindness and Disability: An International Overview. JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS 2020. [DOI: 10.1177/0145482x8908300309] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
For professionals conducting research in the fields of blindness and disability, searching the literature by computer offers speedy access to existing data and facilitates the efficient exchange of information. As computer use becomes more prevalent on an international scale, it is useful for researchers to have knowledge of online searching procedures and resources. This overview outlines important databases produced in the United States and elsewhere, where relevant articles and information may be found.
Collapse
|
13
|
Rosen L, Kislev S, Bar-Zeev Y, Levine H. Historic tobacco legislation in Israel: a moment to celebrate. Isr J Health Policy Res 2020; 9:22. [PMID: 32366296 PMCID: PMC7199353 DOI: 10.1186/s13584-020-00384-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Accepted: 04/27/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Israel was once a leader in tobacco control, but fell behind other countries, particularly during the past decade, as smoking rates stagnated. TEXT: Landmark tobacco control legislation, which banned advertising (with the exception of the print press) and limited marketing, was passed in Israel on Dec. 31rst, 2018. The changes occurred following years of attempts which culminated in successful last-minute efforts to promote the legislation just before the early disbanding of the 20th Knesset (Israeli Parliament). Regulations concerning marketing and advertising were substantially strengthened to address all tobacco, nicotine and smoking products. Digital media was included for the first time. Electronic cigarettes, which were previously largely unregulated, now fall under existing tobacco legislation. The changes overcame intense opposition from the tobacco lobby, and occurred despite the fact that the basic elements for prevention policy postulated by the Richmond model were not in place. CONCLUSIONS This legislation represents an important and long-awaited change in Israeli tobacco control policy. Many deficiencies in existing tobacco control regulation were overcome, and some measures went beyond current international regulations. The cohesive partnership between legislators, public health organizations and professionals, advocacy groups, academia, and leading journalists was critical to this success. The progress was lauded by the World Health Organization with its highest award for tobacco control, which was presented to Smoke Free Israel. This case study provides important lessons for up-to-date tobacco control policy, in the age of rapid global changes in the tobacco, vaping and nicotine landscape.
Collapse
|
14
|
Rosen L. In Brief …. JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS 2020. [DOI: 10.1177/0145482x8708100914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
15
|
Kossl K, Rosen L, Copperman A, Kolev V, Zakashansky K. 37: Use of colpotomy for contained tissue extraction during laparoscopic myomectomy. Am J Obstet Gynecol 2020. [DOI: 10.1016/j.ajog.2019.12.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Evans R, Tanaka S, Tanaka S, Touno S, Shimizu K, Sakui S, Wu J, Faessel H, Hang Y, Alexander R, Rosen L, Hartman D. A Phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.290] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Farago A, Kummar S, Moreno V, Patel J, Lassen U, Rosen L, Ku N, Cox M, Nanda S, Childs B, Hyman D, Drilon A. MA09.07 Activity of Larotrectinib in TRK Fusion Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.570] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Fakih M, Wang D, Harb W, Rosen L, Mahadevan D, Berlin J, Basciano P, Brown R, Arogundade O, Cox C, Genova GD, Krige D, McElwaine-Johnn H. SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.089] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
19
|
Drilon A, Kummar S, Moreno V, Patel J, Lassen U, Rosen L, Childs B, Nanda S, Cox M, Ku N, Farago A. Activity of larotrectinib in TRK fusion lung cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Rosen L, Finkelstein M, Murphy K, Fenske S, Kolev V, Ascher-Walsh C, Zakashansky K. 62: Robotic-assisted laparoscopy versus conventional laparoscopy for the treatment of endometriosis in New York state, 2009-2016. Am J Obstet Gynecol 2019. [DOI: 10.1016/j.ajog.2019.01.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
21
|
Moreno V, Gil-Martin M, Johnson M, Aljumaily R, Lopez Criado P, Northfelt D, Crittenden M, Jabbour S, Rosen L, Garrido P, Hervás Morón A, Rietschel P, Mohan K, Li J, Stankevich E, Feng M, Lowy I, Fury M. Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy487.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Moreno V, Gil-Martin M, Johnson M, Aljumaily R, Lopez Criado P, Northfelt D, Crittenden M, Jabbour S, Rosen L, Garrido Lopez P, Hervás Morón A, Rietschel P, Mohan K, Li J, Stankevich E, Rowlands T, Feng M, Lowy I, Fury M. Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Moreno V, Gil-Martin M, Johnson M, Aljumaily R, Lopez-Criado M, Northfelt D, Crittenden M, Jabbour S, Rosen L, Calvo E, Papadopoulos K, Garrido P, Hervás Morón A, Rietschel P, Mohan K, Li J, Stankevich E, Feng M, Lowy I, Fury M. MA04.01 Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.340] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Gaigbe-Togbe B, Roy-McMahon C, Rosen L, Huntly J, Ahron D, Ascher-Walsh C. Risk Factors for an Extended Length of Stay in Patients Undergoing Robot-Assisted Laparoscopic Myomectomy, a 10-Year Review. J Minim Invasive Gynecol 2017. [DOI: 10.1016/j.jmig.2017.08.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Short GF, Rosen L, Liu J, Hegarty B, Szegda J, Westphal C, Cermak J, Wessel T. 1164 THE USE OF CHEMICAL NEURO STIMULATION TO MINIMIZE SLEEP DISTURBANCE ASSOCIATED WITH MUSCLE CRAMPING AND SPASTICITY. Sleep 2017. [DOI: 10.1093/sleepj/zsx050.1163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|